Morquio syndrome, also known as mucopolysaccharidosis type IV (MPS-IV), is a rare inherited lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine 6-sulfatase (GALNS). This enzyme is responsible for breaking down glycosaminoglycans (GAGs), long chains of sugar molecules important for healthy cellular functioning. Without sufficient GALNS enzyme activity, GAGs accumulate abnormally in tissues and organs throughout the body. Over time, this buildup causes progressive damage and symptoms of the disease.
There are two primary types of Morquio syndrome - Morquio A (MPS IVA), caused by GALNS deficiency, and the extremely rare Morquio B (MPS IVB). Morquio A accounts for approximately 95% of all MPS IV cases. Symptoms tend to appear in early childhood and worsen with age. Common signs include skeletal abnormalities such as short stature, spinal deformities, flattened nasal bridge, protruding sternum, and joint stiffness. Other complications can include heart and respiratory issues, hearing loss, hernias, liver and spleen enlargement, and dental problems. While intelligence is unaffected, physical limitations reduce quality of life and life expectancy. Currently, there is no cure for Morquio Syndrome (MPS-IV) Drug and treatment focuses on managing symptoms.
New Therapies in Development
Considerable research efforts over the past decade aim to develop effective disease-modifying therapies for Morquio A. Enzyme replacement therapy (ERT) involves administering recombinant versions of the defective GALNS enzyme intravenously to facilitate uptake into cells. Vimizim (elosulfase alfa) was approved by the FDA in 2014 as the first ERT for Morquio Syndrome (MPS-IV) Drug. clinical trials found Vimizim significantly reduced urinary GAG levels in patients aged 5 and older with a manageable safety profile. However, there were limitations in achieving clinically meaningful outcomes related to skeletal abnormalities, motor function, and endurance.
More recently, the Phase 3 PERFECT and PERFECT Pediatric studies evaluated the efficacy and safety of vosoritide, a C-type natriuretic peptide analog, in children with Morquio A. Results published in 2021 showed vosoritide significantly increased annualized growth velocity versus placebo after one year of treatment. It also stabilized abnormalities in skeletal disproportion that worsen growth potential. These findings represent an important milestone, with vosoritide being the first drug to potentially address the root cause of skeletal dysplasia in Morquio A. Biomarin Pharmaceutical is seeking regulatory approval for vosoritide globally.
Another promising approach in development is gene therapy. Using modified viruses to deliver functioning GALNS genes directly into the body aims to restore enzyme production in tissues and cells. AVROBIO’s investigational gene therapy AVR-RD-02 achieved proof of concept in a Phase 1/2 trial. Four out of five pediatric patients demonstrated lowered urinary GAG levels. A larger Phase 2 trial is ongoing to further evaluate efficacy and safety of a single dose. Additionally, REGENXBIO is advancing RGN-929, an AAV9 gene therapy delivering GALNS, with plans to initiate pivotal studies this year. The potential for a one-time treatment that could correct the genetic basis of Morquio A raises hope for a disease-modifying therapy.
Accessing Existing and Emerging Therapies
While new treatments generate hope, access and affordability remain key challenges globally—especially for ultra-rare disorders like Morquio Syndrome (MPS-IV) Drug affecting only a few thousand worldwide. Vimizim requires bi-weekly infusions over a patient’s lifetime, costing hundreds of thousands per year. The developer Genzyme operates patient assistance programs to help eligible families gain coverage and reduce out-of-pocket costs in approved countries. However, access discrepancies exist between public healthcare systems and private insurers.
Vosoritide also carries a substantial price tag if approved. Biomarin committed to responsible pricing and expanded access plans to evaluate each child's situation. As with other gene and cell therapies, one-time gene therapy doses for Morquio A would likely exceed $1 million initially, though long-term costs may be similar or less than lifetime ERT. Treatment reimbursement policy will factor heavily in patient access. Groups like the National Organization for Rare Disorders advocate for fair processes and coverage standards to be established proactively.
International consortiums connecting specialized clinics also aid in coordinating multi-disciplinary care, clinical trials recruitment, and support across borders. Telehealth expanded during the COVID-19 pandemic benefited remote communities. Further global awareness and coordination aims to give all Morquio syndrome patients equal opportunity to benefit from ongoing therapeutic advances, regardless of geography. Continued dedication from researchers, patient advocates and governments will be crucial moving forward.
Get more insights on Morquio Syndrome (MPS-IV) Drug
Enzyme replacement therapy market is a medical therapy used for treatment of congenital enzyme deficiencies by using human and animal or recombinant engineered enzymes.
Intravenous and oral routes of administration are often used for ERT.
Enzyme replacement therapies are applied in some lysosomal storage diseases such as Gaucher disease, Pompe disease, Hurler syndrome among others.The prevalence rate of lysosomal storage diseases is approximately 5000 live births that include Gaucher disease and Hurler syndrome and others.
The prevalence of rare diseases in the United States is estimated to be 25-30 million population.
Enzyme replacement therapies and anticipated in treatment of these diseases.Enzyme replacement therapy market is rising gradually with a healthy CAGR of 11.05% in the forecast period of 2019-2026.
Participation of many pharmaceutical companies in development of enzyme replacement therapies and governmental support for research and development are some factors that bring healthy opportunities for the market growth.This Enzyme Replacement Therapy Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry.
The latest trending report Global Enzyme Replacement Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.
The report will assist reader with better understanding and decision making.The Enzyme Replacement Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.This report also researches and evaluates the impact of Covid-19 outbreak on the Enzyme Replacement Therapy industry, involving potential opportunity and challenges, drivers and risks.
We present the impact assessment of Covid-19 effects on Enzyme Replacement Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.
).Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/29810-enzyme-replacement-therapy-market-analysis-reportThe major players covered in Enzyme Replacement Therapy are:SanofiJohnson & JohnsonAbbVieTakedaHorizon PharmaBioMarinRecordati Rare DiseasesAllerganAlexionActelionPfizerDigestive CareLeadiant BiosciencesBy Type, Enzyme Replacement Therapy market has been segmented intoInjectable AgentsOral AgentsBy Application, Enzyme Replacement Therapy has been segmented into:Gaucher DiseaseFabry DiseaseMPS DiseaseGastrointestinal DiseaseOthersThe report offers in-depth assessment of the growth and other aspects of the Enzyme Replacement Therapy market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, etc.
)Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Enzyme Replacement Therapy Market @ https://www.decisiondatabases.com/contact/download-sample-29810The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Enzyme Replacement Therapy product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Enzyme Replacement Therapy, with price, sales, revenue and global market share of Enzyme Replacement Therapy in 2018 and 2019.Chapter 3, the Enzyme Replacement Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Enzyme Replacement Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Enzyme Replacement Therapy market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Enzyme Replacement Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Enzyme Replacement Therapy Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-29810Other Reports by DecisionDatabases.com:Global Negative Pressure Wound Therapy Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Hormone Replacement Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025Global Oncolytic Virus Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
